Equine Herpesvirus-1 (EHV-1) is one of the most serious infectious diseases facing horse owners today. This highly contagious virus spreads rapidly through horse populations and can cause significant illness, reproductive loss, and in severe cases, neurological complications and death. Understanding EHV-1 outbreaks is essential for anyone who owns, manages, or cares for horses, particularly those operating boarding facilities or managing herds with multiple animals. While EHV-1 has been endemic in the equine population for decades, periodic outbreaks serve as stark reminders of how quickly this virus can spread and the importance of biosecurity measures on any equine property.
This article provides horse owners and caretakers with practical, evidence-based information about EHV-1 outbreaks, including how the virus spreads, the clinical signs to recognize, quarantine and management strategies, and vaccination protocols. The information presented here is educational and does not replace consultation with a licensed equine veterinarian. For urgent symptoms such as fever above 105 degrees Fahrenheit, severe neurological signs, or acute respiratory distress, contact an equine veterinarian immediately.
What is EHV-1 and Why Does It Cause Outbreaks?
Equine Herpesvirus-1 is a double-stranded DNA virus that belongs to the herpesvirus family. It is closely related to EHV-4, another equine herpesvirus, but EHV-1 is generally considered more virulent and pathogenic. The virus is endemic worldwide and affects horses of all ages and breeds, though young horses (under 3 years), pregnant mares, and immunocompromised animals are at higher risk for severe disease.
EHV-1 spreads through respiratory secretions, nasal discharge, saliva, urine, feces, and aborted fetal tissue. The virus can also be transmitted via contaminated equipment, clothing, vehicles, and hands. An infected horse may shed the virus for 7 to 10 days during the acute respiratory phase, but the virus can remain latent in nerve tissue and reactivate later, particularly during stress. This latency and reactivation cycle makes EHV-1 difficult to eliminate from a herd and a primary reason why outbreaks can recur unexpectedly.
Clinical Signs of EHV-1 Infection
Respiratory Disease
The most common presentation of EHV-1 is respiratory disease. Infected horses typically develop fever, often reaching 104 to 107 degrees Fahrenheit, within 1 to 3 days of exposure. Other early signs include nasal discharge (which may be clear or mucopurulent), coughing, depression, loss of appetite, and enlarged lymph nodes in the head and neck. Respiratory signs usually peak within 7 to 10 days and may resolve within 2 to 3 weeks, though secondary bacterial infections can complicate recovery and prolong illness.
Reproductive Disease
In pregnant mares, EHV-1 can cause abortion, typically in the third trimester but sometimes earlier. Abortions associated with EHV-1 may occur with or without preceding respiratory signs, sometimes weeks after initial infection. Aborted fetuses and placental tissue are highly infectious and represent a major biosecurity hazard. Mares may also experience retention of fetal membranes or secondary uterine infections following abortion.
Neurological Disease (EHV-1 Myeloencephalopathy)
A concerning manifestation of EHV-1 is neurological disease, referred to as EHV-1 myeloencephalopathy (EHM). This form occurs in approximately 1 to 10 percent of EHV-1 infections and results from viral invasion of the central nervous system. Clinical signs develop acutely and may include hind limb ataxia (incoordination), weakness, urinary retention, fecal incontinence, loss of tail tone, and in severe cases, recumbency (inability to stand). Neurological signs can appear with or without respiratory signs, making diagnosis challenging. The prognosis varies; some horses recover fully, while others experience permanent neurological deficits or die.
Recognition and Diagnosis of an EHV-1 Outbreak
An EHV-1 outbreak is typically recognized when multiple horses at a facility develop fever, respiratory signs, or other clinical signs consistent with the virus within a short time frame. On a boarding facility or breeding operation with 20 to 40 horses, an outbreak may affect 10 to 30 percent of the herd within 2 to 4 weeks if biosecurity measures are not implemented immediately.
Diagnosis is confirmed through nasopharyngeal or nasal swab samples tested via polymerase chain reaction (PCR) or virus isolation, blood serum PCRs, or aborted fetal tissue testing. A veterinarian may also use clinical signs, herd history, and bloodwork to support a presumptive diagnosis. Testing should begin as soon as EHV-1 is suspected, as early confirmation allows for rapid implementation of quarantine protocols.
Quarantine and Management During an Outbreak
Once EHV-1 is confirmed or strongly suspected, strict quarantine measures must be implemented immediately to prevent spread to other horses on the property and to neighboring facilities.
Essential Quarantine Protocols
- Isolate affected horses: Move sick or confirmed positive horses to a separate barn or paddock area at least 100 feet away from other horses, with separate fencing if possible.
- Restrict movement: Do not move horses on or off the property except for emergency veterinary care.
- Dedicated staff and equipment: Assign specific caretakers to handle quarantined horses, and keep all equipment, feed buckets, grooming supplies, and tack separate.
- Hand hygiene: Wash hands thoroughly and change clothing after handling affected horses or entering quarantine areas.
- Disinfection: Clean and disinfect equipment, gates, water troughs, and any shared surfaces with a quaternary ammonium-based disinfectant or 10 percent bleach solution.
- Monitor unexposed horses: Take daily temperatures on all other horses and watch for clinical signs. Quarantine any new horses showing signs.
- Coordinate with neighbors: Notify boarding facilities and farms within a few miles to alert them to the outbreak, allowing them to heighten biosecurity.
Treatment and Supportive Care
No specific antiviral treatment exists for EHV-1 in horses. Management focuses on supportive care: stall rest, pain relief, febrifuges (fever reducers) such as phenylbutazone or firocoxib, and monitoring for secondary complications. Horses with respiratory disease benefit from good ventilation, clean water, and high-quality forage. Horses showing neurological signs require careful nursing, frequent recumbent horse turns if bedbound, and assessment for urinary or fecal retention. In severe cases, hospitalization at an equine clinic may be necessary.
Duration of Quarantine and Return to Normal
The quarantine period depends on the situation. For individual confirmed cases, quarantine is typically maintained for a minimum of 7 to 14 days after the horse has recovered and shown no fever for at least 48 hours. For facility outbreaks, quarantine may last 3 to 4 weeks after the last new case appears. Some veterinarians recommend extended quarantine periods (up to 4 to 6 weeks) due to the risk of viral shedding and latent reactivation.
Before lifting quarantine, work with your veterinarian to confirm that affected horses are clinically normal, have been afebrile for at least 2 days, and show no respiratory or other signs. Grazing isolation (separate pasture) for an additional week or two provides an extra safety margin.
Vaccination Against EHV-1
Vaccine Types and Efficacy
Several EHV-1 vaccines are available, including inactivated whole-virus vaccines and modified-live vaccines. Most commonly, vaccines are components of combination products that also protect against EHV-4 and other equine respiratory viruses. Vaccination does not prevent infection entirely but significantly reduces the severity of respiratory disease, lowers fever, and reduces viral shedding. Vaccines are less effective at preventing abortion or neurological disease, underscoring the importance of biosecurity.
Vaccination Recommendations
The American Association of Equine Practitioners (AAEP) recommends annual vaccination of horses with EHV-1/EHV-4 combination vaccines as part of a core vaccination program. Breeding mares should be vaccinated at specific times during pregnancy (typically during the 5th, 7th, and 9th months of gestation) to reduce the risk of abortion. Young horses should begin the vaccine series at 4 to 6 months of age with boosters every 4 to 6 weeks until 1 year of age, then annually.
Horses at high risk, including those at boarding facilities, breeding operations, or show facilities, may benefit from more frequent boosters (every 6 months). However, vaccination during an active outbreak is not recommended, as the immune response may be compromised in actively infected animals.
Preventing EHV-1 Outbreaks: Biosecurity Strategies
Prevention is far more effective than managing an outbreak. Implement the following biosecurity measures year-round:
- Vaccinate all horses annually against EHV-1/EHV-4 and maintain booster schedules.
- Quarantine new arrivals for 2 to 3 weeks before introducing them to the main herd, monitoring for fever and respiratory signs daily.
- Minimize horse movement to shows, sales, and other facilities, and isolate returning horses for 2 to 3 weeks.
- Maintain separate equipment, feed buckets, and grooming supplies for each horse when possible.
- Practice rigorous hand and boot hygiene, especially when handling multiple horses.
- Clean and disinfect water troughs, feeders, and common areas regularly.
- Maintain good ventilation in barns and avoid overcrowding.
- Work with your veterinarian to establish an outbreak response plan before one occurs.
Special Considerations: Neurological Cases and Abortion
Horses with EHV-1 myeloencephalopathy require intensive nursing and may need months of recovery. Work closely with an equine veterinary neurologist or internist for diagnosis (such as cerebrospinal fluid analysis) and treatment protocols. Recovery is unpredictable; some horses regain full function, while others may not.
Aborted fetuses and placental tissue must be handled as highly infectious biohazard material. Use gloves and a mask when handling, and consult your veterinarian on safe disposal methods. Do not allow other horses to contact aborted material.
Reporting and Legal Considerations
EHV-1 outbreaks, particularly those with neurological or reproductive involvement, should be reported to your state or local animal health authority or veterinary board. Facilities operating boarding, breeding, or show operations may be required to report outbreaks. Transparency and cooperation with authorities protect the wider equine community and demonstrate responsible management.
Frequently Asked Questions
How long does EHV-1 immunity last after vaccination?
Vaccination-induced immunity wanes over 6 to 12 months, which is why annual boosters are recommended. Immunity is improved in horses that have been both vaccinated and previously exposed to the virus, though prior exposure alone (without vaccination) does not provide reliable protection against severe disease.
Can humans catch EHV-1 from horses?
No, EHV-1 does not infect humans. However, humans can carry the virus on hands, clothing, and equipment, making hand hygiene and equipment sanitation critical during outbreaks.
Is it safe to ride a horse recovering from EHV-1?
Most horses recovering from uncomplicated respiratory EHV-1 can resume light work within 3 to 4 weeks, once fever has resolved and they are eating and breathing normally. Horses recovering from neurological disease should not be ridden until they have regained full coordination and strength, which may take weeks to months. Always consult your veterinarian before returning to work.
What is the mortality rate of EHV-1?
Overall mortality from EHV-1 respiratory disease is low, typically less than 5 percent in adult horses with appropriate supportive care. However, mortality rises in young foals, immunocompromised horses, and cases complicated by severe secondary infections or neurological disease, where mortality may reach 10 to 15 percent or higher.
Key Takeaways
- EHV-1 is a highly contagious virus causing respiratory disease, abortion, and neurological disease (EHM) in horses of all ages.
- The virus spreads via respiratory secretions and fecal-oral contact; strict quarantine and biosecurity are essential during outbreaks.
- Clinical signs include fever, nasal discharge, cough, depression, and in severe cases, hind limb weakness and ataxia.
- Diagnosis is confirmed by PCR testing of nasal swabs, blood, or fetal tissue; suspected cases should be isolated immediately.
- Treatment is supportive; no specific antiviral exists. Quarantine typically lasts 2 to 6 weeks depending on herd impact.
- Annual EHV-1/EHV-4 vaccination, strategic booster schedules for high-risk horses, and comprehensive biosecurity measures are the foundation of prevention.
- Pregnant mares should receive booster vaccinations during the 5th, 7th, and 9th months of pregnancy to reduce abortion risk.
- Consult an equine veterinarian immediately for fever above 105 degrees, respiratory distress, neurological signs, or abortion on your property.
Leave a Reply